Miragen, University of Colorado Collaborate on microRNA Research | GenomeWeb

Miragen Therapeutics said this week that it has formed a sponsored research and licensing arrangement with the University of Colorado focused on microRNA therapeutics.

Under the sponsored-research portion of the deal, Miragen will fund the analysis of miRNA and gene-expression changes from a study of beta blocker effects on cardiac remodeling and gene expression conducted at the University of Colorado Cardiovascular Institute at the UC Denver School of Medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.